Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial (Nature Medicine, (2022), 28, 10, (2092-2099), 10.1038/s41591-022-02011-x)

Jeremy Pettus, Schafer C. Boeder, Mark P. Christiansen, Douglas S. Denham, Timothy S. Bailey, Halis K. Akturk, Leslie J. Klaff, Julio Rosenstock, Mickie H.M. Cheng, Bruce W. Bode, Edgar D. Bautista, Ren Xu, Hai Yan, Dung Thai, Satish K. Garg, Samuel Klein

Research output: Contribution to journalComment/debate

Abstract

Correction to: Nature Medicine, published online 3 October 2022. In the version of this article initially published, the ClinicalTrials.gov registration number, NCT03117998, was missing from the Abstract. It has now been inserted in the HTML and PDF versions of the article.

Original languageEnglish
Pages (from-to)2959
Number of pages1
JournalNature medicine
Volume29
Issue number11
DOIs
StatePublished - Nov 2023

Fingerprint

Dive into the research topics of 'Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial (Nature Medicine, (2022), 28, 10, (2092-2099), 10.1038/s41591-022-02011-x)'. Together they form a unique fingerprint.

Cite this